Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
BMTC Group (TSE:GBT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?
04:38am, Saturday, 07'th Feb 2026
BMTC Group Inc. (TSE: GBT - Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$12.98 and traded as low as C$12.80. BMTC Group
BlackLine Celebrates Top Companies Driving the Future of Financial Operations
09:00am, Monday, 08'th Sep 2025
Honorees include American Express Global Business Travel, Wendy's, and Cavco, recognized for achieving significant transformational outcomes LOS ANGELES , Sept. 8, 2025 /PRNewswire/ -- BlackLine (Nasd
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
10:20am, Thursday, 06'th Oct 2022 Zacks Investment Research
Style Box ETF report for FYC
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
10:20am, Thursday, 29'th Sep 2022 Zacks Investment Research
Style Box ETF report for FYX
Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer
04:00pm, Monday, 26'th Sep 2022 GlobeNewswire Inc.
Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer
Guerbet obtient le financement d’un million d’euros de la Banque Publique d’Investissement(BPI projet France 2030) pour son projet d’intelligence artificielle dans la détection précoce du c
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
10:20am, Friday, 23'rd Sep 2022 Zacks Investment Research
Smart Beta ETF report for XBI
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
05:00pm, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
Guerbet annonce l'approbation par la FDA du produit de contraste Elucirem™ (Gadopiclénol)
05:00pm, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
Guerbet annonce l'approbation par la FDA du produit de contraste EluciremTM (Gadopiclénol)
GUERBET: Résultats semestriels 2022
03:45pm, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
Résultats semestriels 2022
Guerbet: 2022 half-year results
03:45pm, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
2022 half-year results
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2022
10:03am, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2022
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
12:41pm, Friday, 16'th Sep 2022
After a slow first half, merger and acquisition deals are heating up for the remainder of 2022. In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Globa
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
10:00pm, Thursday, 15'th Sep 2022 GlobeNewswire Inc.
Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease Patients Congress Moves to Expand Funding for National Networ
Global Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue?
03:30pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
